Capricor Therapeutics Inc (NASDAQ:CAPR) Short Interest Update

Capricor Therapeutics Inc (NASDAQ:CAPR) was the target of a significant decrease in short interest in the month of October. As of October 31st, there was short interest totalling 5,280,000 shares, a decrease of 14.6% from the October 15th total of 6,180,000 shares. Based on an average daily volume of 2,990,000 shares, the short-interest ratio is presently 1.8 days.

Capricor Therapeutics Stock Up 0.6 %

NASDAQ:CAPR traded up $0.12 during midday trading on Friday, hitting $18.61. The stock had a trading volume of 929,811 shares, compared to its average volume of 1,147,541. Capricor Therapeutics has a one year low of $2.87 and a one year high of $23.40. The company has a market capitalization of $845.08 million, a price-to-earnings ratio of -17.56 and a beta of 4.00. The stock has a 50-day moving average of $15.21 and a 200 day moving average of $8.46.

Insider Buying and Selling at Capricor Therapeutics

In related news, major shareholder Shinyaku Co Ltd Nippon acquired 2,798,507 shares of the firm’s stock in a transaction on Friday, September 20th. The shares were acquired at an average cost of $5.36 per share, for a total transaction of $14,999,997.52. Following the completion of the transaction, the insider now directly owns 7,090,351 shares in the company, valued at approximately $38,004,281.36. This trade represents a 65.21 % increase in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Company insiders own 12.00% of the company’s stock.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently bought and sold shares of the company. BNP Paribas Financial Markets bought a new stake in Capricor Therapeutics during the 1st quarter valued at $40,000. Main Street Financial Solutions LLC boosted its position in Capricor Therapeutics by 37.5% during the 2nd quarter. Main Street Financial Solutions LLC now owns 27,500 shares of the biotechnology company’s stock valued at $131,000 after acquiring an additional 7,500 shares in the last quarter. SG Americas Securities LLC bought a new stake in Capricor Therapeutics during the 3rd quarter valued at $133,000. Bank of New York Mellon Corp boosted its position in Capricor Therapeutics by 12.8% during the 2nd quarter. Bank of New York Mellon Corp now owns 79,782 shares of the biotechnology company’s stock valued at $381,000 after acquiring an additional 9,040 shares in the last quarter. Finally, The Manufacturers Life Insurance Company bought a new stake in Capricor Therapeutics during the 3rd quarter valued at $161,000. Institutional investors own 21.68% of the company’s stock.

Analyst Ratings Changes

A number of research analysts have recently commented on CAPR shares. Cantor Fitzgerald upped their target price on Capricor Therapeutics from $25.00 to $30.00 and gave the company an “overweight” rating in a research note on Thursday. Maxim Group upped their target price on Capricor Therapeutics from $12.00 to $25.00 and gave the company a “buy” rating in a research note on Wednesday, September 25th. Piper Sandler started coverage on Capricor Therapeutics in a research note on Monday, October 21st. They set an “overweight” rating and a $35.00 target price on the stock. HC Wainwright reaffirmed a “buy” rating and set a $77.00 target price on shares of Capricor Therapeutics in a research note on Thursday. Finally, Oppenheimer reaffirmed an “outperform” rating and set a $15.00 target price on shares of Capricor Therapeutics in a research note on Monday, September 23rd. One investment analyst has rated the stock with a sell rating and six have assigned a buy rating to the company. According to MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average price target of $34.50.

About Capricor Therapeutics

Capricor Therapeutics, Inc (NASDAQ:CAPR) is a clinical-stage biotechnology company focused on the discovery, development and commercialization of first-in-class biological therapeutics for the treatment of rare disorders. Capricor’s lead candidate, CAP-1002, is an allogeneic cell therapy that is currently in clinical development for the treatment of Duchenne muscular dystrophy.